… increased recurrence risk among patients with EGFR-positive NSCLC and distinct from
wildtype EGFR NSCLC. To this end, we developed an individual patient nomogram of routine …

… pre-treatment PD-L1 might be used to categorize different … , leading to distinct clinical
outcomes and varied potentials to … first-line treatment of advanced non-small-cell lung cancer with …

… This has led to superior patient outcomes when used as a monotherapy over traditional …
This agent was evaluated in phase III studies in two different settings: initially, in second-line …

… epidermal growth factor receptor (EGFR)-TKI treatment … into non-small cell lung cancer
(NSCLC) and small cell lung … Baseline characteristics were stratified according to different-…

… Non-small cell lung cancer … mutations in the epidermal growth factor receptor (EGFR) gene,
treatment with EGFR … or treated outside the Flatiron network could have different outcomes. …

… If in future versions of this review we identify trials comparing different interventions that
are similar enough in their populations and outcomes, we may make indirect comparisons for …

… Our study was unique in that it also examined the prevalence of the most prominent TKI-sensitizing
submutations. Although there were regional differences in the distribution of …

… After surgery, distinct metastatic patterns were revealed according to EGFR mutation status.
… and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients …

… Epithelial growth factor receptor (EGFR) is a cell surface … the extracellular messages inside
the cell and thereby alter the … to most advanced clinical studies with different combination …

… In addition, with the introduction of different NGS gene approach an improvement of EGFR
… patients with these mutations from the analysis to define the clinical outcome (LUX-Lung 2, 3 …